Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trialMarta Mosca, Vibeke Strand, Laurent Arnaud et al.|Lupus Science & Medicine|2025Cited by 5
LO-015 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial in systemic lupus erythematosus (SLE): achievement of sustained SRI(4), BICLA, and dual responses over 48 weeksRichard Furie, Eric F. Morand, Cristina Arriens et al.|Unknown|2023Cited by 0
P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trialRonald van Vollenhoven, Eric F. Morand, Joseph F. Merola et al.|Poster presentations|2024Cited by 0
P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY studyMarilyn C. Pike, Joan T. Merrill, Amit Saxena et al.|Poster presentations|2024Cited by 0